One gene helps drive growth in two childhood brain tumor groups that lack targeted therapies
Targeting KDM2B or downstream protein complexes it recruits may exploit a vulnerability in high-risk medulloblastoma subgroups that currently lack targeted therapies, according to a study led by St. Jude Children's Research Hospital and Hopp Children's Cancer Center Heidelberg (KiTZ). The researchers found that Group 3 and Group 4 medulloblastomas depend on the protein KDM2B for growth and that…
A study from St. Jude Children's Research Hospital and Hopp Children's Cancer Center Heidelberg reveals that KDM2B, an epigenetic regulator, drives tumor growth in two high-risk medulloblastoma subgroups that currently have no targeted therapies. Group 3 and Group 4 medulloblastomas depend on KDM2B for growth, and removing or degrading the gene for KDM2B or its protein slows tumor growth in preclinical models.
These findings, published in Nature Genetics, could lead to new therapeutic strategies for these aggressive childhood brain tumors.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
